
AbbVie scores speedy review for RA drug upadacitinib; Merck KGaA wins CRISPR patent
→ AbbVie $ABBV has high hopes, projecting peak potential sales of $6.5 billion, for its oral JAK1 inhibitor upadacitinib for rheumatoid arthritis, which is up against well-entrenched rivals. On Tuesday, the drugmaker said FDA had rewarded the drug — which is also under EU review — priority review, and that the US health regulator is expected to makes its decision by the third quarter of 2019.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters